Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program
HEMISPHERX BIOPHARMA (HEB)
NASDAQ:AMEX Investor Relations:
hemispherx.net/mobile/investor-relations.php
Company Research
Source: GlobeNewswire
OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapies, such as checkpoint blockade therapies. This second update follows the company’s first quarterly Ampligen update on March 13. The company has five ongoing immuno-oncology clinical trials, four planned clinical trials and an active Early Access Program (EAP). The most recent addition to the ongoing group is a clinical study in the treatment of prostate cancer, where FDA authorization has been received. “Thus far, we have had steady and consistent clinical progress in immuno-oncology. I believe this is critical to creating long-term stockholder value, as success in any one of our trials has the potential to be a strong driver of the market,” said Hemispherx CEO Thomas K. Equels. “Especi
Show less
Read more
Impact Snapshot
Event Time:
HEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HEB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HEB alerts
High impacting HEMISPHERX BIOPHARMA news events
Weekly update
A roundup of the hottest topics